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Direct demonstration of insulin-like growth factor-I-induced nitric
oxide production by endothelial cells. Several lines of evidence indicate
that insulin-like growth factor-I (IGF-I) is a potent mediator of vasodi-
lation. To elucidate the mechanism and site of action of IGF-I, we
performed continuous monitoring of nitric oxide (NO) release from
endothelial cells using a highly-sensitive amperometric NO-sensor.
Two types of cultured cells were used: human umbilical vein endothe-
hal cells and immortalized rat renal interlobar artery endothehial cells.
In separate experiments, [Ca211 changes in response to IGF-I were
measured spectrofluorometrically in fura-2-loaded cells. Stimulation
with IGF-I resulted in a rapid, dose-dependent increase in [NO] as
detected by the NO-probe positioned 1 mm above the monolayers,
followed by a sustained elevation lasting for at least five minutes. The
effect of IGF-I was significantly suppressed by pretreatment with
anti-lOP-I antibody, suggesting that it was specific for IGF-I. N°-nitro-
L-arginine methyl ester, an inhibitor of NO synthesis, significantly
blunted responses to IGF-I, but dexamethasone preincubation did not
reduce the IGF-I-induced release of NO. These results indicate that the
observed IGF-I-induced release of NO is a result of activation of the
constitutive, rather than the inducible type of NO synthase in endothe-
lial cells. Genistein, a tyrosine kinase inhibitor, resulted in a profound
suppression of the IGF-I-induced release of NO. IGF-I did not affect
[Ca2], in either type of cells. Therefore, IGF-I-induced NO production
by both types of endothelial cells is mediated via a tyrosine kinase-
dependent mechanism. IGF-I may be an important regulator of vascular
tone in vivo through NO release from the vascular endothehium, and
may contribute to the regulation of renal blood flow under physiological
and pathophysiological conditions.
Insulin-like growth factor-I (IGF-I) is a polypeptide (molec-
ular wt 7,646 Daltons) which stimulates growth, differentiation
and metabolism of various tissues through its specific high-
affinity receptor [1—3]. In addition to these effects, IGF-I
appears to be implicated in the regulation of vascular tone [1, 31.
Recent studies performed in humans [41 and rats [5—7] demon-
strated an increase in renal blood flow and glomerular filtration
rate and a decrease in renal vascular resistance upon the
infusion of recombinant human IGF-I. Although the precise
mechanism(s) of such action of IGF-I remains to be determined,
discovery of specific receptors for IGF-I on the vascular
endothelium [8—10] raises an intriguing possibility that the renal
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vasodilatory action of IGF-I could be mediated by some endo-
genous vasodilator(s) synthesized by the endothelium.
Hirschberg and Kopple [5] suggested that IGF-I-induced
renal vasodilation is attributed to an increased synthesis of
prostacyclin by the endothelium, since the vasodilatory re-
sponse to IGF-I was reduced by a cyclo-oxygenase inhibitor,
indomethacin. More recently, Haylor, Singh and El Nahas [6]
have advocated the involvement of nitric oxide (NO) synthesis
in the action of IGF-I. These investigators have demonstrated
that the effects of IGF-I were completely blocked by N°-nitro-
L-arginine methyl ester (L-NAME), a competitive inhibitor of
NO biosynthesis, but only partially reduced by indomethacin.
NO, which is synthesized from L-arginine [11, 12] by an
NADPH and Ca2/ca1modulin dependent enzyme, nitric oxide
synthase (NOS) [13, 14], is a potent vasodilator and inhibitor of
platelet aggregation [15]. We have recently adapted a highly-
sensitive amperometric NO-sensor to the continuous monitor-
ing of NO release from cultured human umbilical vein endothe-
hal cells (HUVEC) [16]. The purpose of the present study was
to perform real-time monitoring of NO release from two types
of cultured endothelial cells, HUVEC and immortalized rat
renal interlobar artery endothelial cells (RIAEC), stimulated
with IGF-I. The results provide the first direct demonstration
that IGF-I stimulates NO release from the vascular endothe-
hum.
Methods
Endothelial cell culture
Primary cultures of HUVEC were prepared according to the
method of Jaffe [17]. Cells were grown in M199 medium
(Mediatech, Washington, D.C.) supplemented with 10% fetal
bovine serum (HyClone Laboratories, Logan, Utah, USA), 30
p,g/ml endothelial cell growth factor (Upstate Biotechnology,
Lake Placid, New York, USA) and 100 g/ml heparin (Elkins-
Sinn, Cherry Hill, New Jersey, USA).
Immortalization of renal resistance artery endothehial cells
was performed as follows. Renal interlobar arteries were mi-
crodissected from kidneys of two five-week-old male Sprague-
Dawley rats. All microdissection procedures were carried out
over ice under sterile conditions. The vessels were macerated
and suspended in cold Spinner's salt solution without Ca2 or
Mg2 (Sigma Chemical, St. Louis, Missouri, USA) buffered
with 25 m N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
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Fig. 1. Characterization ofSV4O-transfected
RIAEC. (A) Nuclear expression of SV4O large
T antigen. Procedures for the staining are
described in the Methods section. Intense
fluorescence is observed in the nuclei of
RIAEC. Magnification x800. (B) HUVEC
show no expression of SV4O large T antigen
(negative control). (C) and (D) Paired phase
contrast and immunofluorescence images,
respectively, of SV4O-transfected RIAEC
showing positive staining with antibody to
factor VIII. Note also that subconfluent cells
tend to form capillary.like structures.
Magnification x400. (E) and (F) Paired phase
contrast and immunofluorescence images,
respectively, of SV4O-transfected RIAEC
showing uptake of acetylated low-density
lipoprotein. Magnification x400.
acid (HEPES), pH 7.4. The suspension was centrifuged twice to
eliminate cellular debris and the final pellet was resuspended in
M199 medium supplemented with 15 ms HEPES and 0.3 mg/ml
collagenase type 1A (Sigma Chemical), pH 7.4. The suspension
was incubated for 90 minutes at 37°C with periodic agitation.
Dissociated cells were centrifuged and the pellet resuspended in
the same culture medium as used for HUVEC culture. When
primary cultures reached semiconfluence, the medium was
aspirated and high-titered (108 virus/mi) wild-type simian virus
40 (SV4O) (provided by Dr. P. Tegtmeyer, Dept. of Microbiol-
ogy, SUNY at Stony Brook) [181 was added for 60 minutes. The
cells were maintained in the same medium which was ex-
changed every three days. Three weeks later, RIAEC were
isolated by limited cloning. Concentration of serum was re-
duced to 5% in the M199 medium and additional supplements
discontinued. Transfection of RIAEC with SV4O was confirmed
immunocytochemically by the demonstration of nuclear expres-
sion of SV4O-specific large T antigen in cultured cells (Fig. 1A).
Cells were grown on 35 mm gelatin-coated dishes at 37°C in
an atmosphere of 95% air-5% CO2. Both types of cells were
identified as endothelial based on the following criteria: distinct
cobblestone-like morphology and positive immunofluorescent
labeling with factor VIII and acetylated low-density lipoprotein
(Fig. 1C-F). The cells were used at passages 3 to 4 for HUVEC
and 8 to 10 for RIAEC.
Immunocytochemical detection of the large T antigen
Identification of nuclear large T antigen in SV4O-transfected
cells was performed on cells grown on coverslips and fixed with
3.3% formaldehyde-phosphate buffer solution (15 mm) followed
by acetone (5 mm at —20°C). Cells were then washed in
phosphate buffer and incubated for one hour at room tempera-
ture with mouse monoclonal antibody specific for large T
antigen (provided by Dr. P. Tegtmeyer, SUNY at Stony
Brook), followed by FITC-labeled anti-mouse IgG for one hour.
Each incubation step was followed by four three-minute washes
with phosphate buffer.
[NO] monitoring
The cells were incubated in 2 ml of Krebs-Henseleit buffer
containing (in mM) 120 NaCl, 4.6 KC1, 1.5 CaCl2, 0.5 MgCl2, 1.5
NaH2PO4, 0.7 Na2HPO4, 10 HEPES and 10 glucose, pH 7.4,
supplemented with 8 U/ml superoxide dismutase derived from
bovine liver (Sigma Chemical).
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NO was measured with a commercially available NO meter
(Iso-NO, World Precision Instruments, Sarasota, Florida,
USA), as detailed previously [161. The principle of measure-
ments and the electrode design have previously been described
[19, 20]. This probe polarographically measures the concentra-
tion of NO gas in aqueous solutions. The sensor probe housing
is covered with a gas-permeable membrane. NO diffusing
through the membrane is oxidized at the working platinum
electrode, resulting in an electrical current. This redox current
is proportional to the rate of diffusion through the membrane,
which is in turn proportional to the NO concentration outside
the membrane. To reduce the noise, the generated redox
current was filtered at 1.1 Hz. For calibration, KNO2 (0.05 mM)
was used as a generator of NO in the K!, H2S04 and K2S04
mixture, based on the following equation: 2KN02 + 2K! +
2H2S04 + 2K2S04 — 2N0 + 12 + 2H20 + 4K2S04.
For experiments, the sensor probe was inserted vertically
into a petri dish with confluent cells and the sensor membrane
was positioned ca. 1 mm above the monolayer using a manual
micromanipulator. The dishes were not capped. All measure-
ments were performed at room temperature.
Cytosolic Ca2 ([Ca2],) measurements
[Ca2i response to IGF-I in HUVEC and RIAEC was
monitored as described previously [21]. The cells were loaded
with 2 p.M fura-2/AM for one hour, washed in Krebs-Henseleit
buffer and placed in a Sykes-Moore chamber (Bello, Vineland,
New Jersey, USA). The chamber was then mounted on the
stage of a Nikon inverted microscope equipped with quartz
optics and coupled to a Deltascan microspectrofluorometer
system (PT!, Princeton, New Jersey, USA). Optically isolated
individual cells were alternately illuminated at wavelengths 345
and 380 nm using a 75-Watt xenon lamp and a chopper. Emitted
light was fed into the photomultiplier via an ultraviolet dichroic
mirror and interference filter 510 nm (Corion, Houston, Massa-
chusetts, USA). Measurements of fluorescence intensity were
performed at a rate of 20 points/sec and 345:380 ratio was
computed using the PTI software.
Materials
The following chemicals were used: rabbit anti-factor VIII
antibody (its production and characterization were described
previously [22]), Dil-acetylated low-density lipoprotein (Bio-
medical Technology, Boston, Massachusetts, USA), recombi-
nant human IGF-I (a gift of Upstate Biotechnology), anti-
human IGF-I antibody (provided by Dr. L.E. Underwood,
Dept. of Pediatrics, University of North Carolina, Chapel Hill,
North Carolina, USA), L-NAME (Bachem California, Tor-
rance, California, USA), dexamethasone (Elkins-Sinn),
genistein (GEN) (Calbiochem, La Jolla, California, USA),
ionomycin (Sigma Chemical), fura-2/AM (Molecular Probes,
Eugene, Oregon, USA).
Calculation and statistical analysis
Results are presented as mean SEM and compared by
one-way analysis of variance using Scheffe's F-test, where P <
0.05 was considered statistically significant.
Results
Calibration of the electrode
The titration method always detected NO standards with
good linearity (r = 0.992 0.003, N = 12), but the sensitivity of
the electrode showed relatively large day-to-day variations
between 1.67 and 3.92 n NO/pA (2.96 0.20 flM NO/pA).
Therefore calibration of the NO-electrode was performed on
each experimental day. The detection limit calculated as a
signal-to-noise ratio of 3 was 8 to 15 flM NO.
Measurement of NO release from endothelial cells
As shown in Figure 2, stimulation of HUVEC or RIAEC with
IGF-I resulted in a rapid rise of [NO] in the bath, followed by a
sustained elevation lasting for at least five minutes. The re-
sponses to IGF-l occurred in a dose (1 to 20 ng/ml)-dependent
fashion in both cell types (Fig. 3).
When the anti-IGF-I antibody was present in the incubation
medium (final dilution 1:4,000), the observed responses to
IGF-I were significantly blunted: the reduction in peak [NO] of
74% in HUVEC and 80% in RIAEC (Figs. 2 and 4). In addition,
preincubation of HUVEC or RIAEC with a competitive inhib-
itor of NOS, 1 m L-NAME for two hours [6] caused a 74% and
81% reduction in peak [NO] responses to IGF-I, respectively
(Figs. 2 and 4). These results indicate that IGF-I specifically
stimulates NO production by the endothelial cells.
NOS in endothelial cells
It has been established that vascular endothelial cells express
two forms of NO synthase, constitutive and inducible NOS
[23]. As shown above, NO production in response to IGF-I was
significantly suppressed upon preincubation of cells with the
universal NOS inhibitor L-NAME. To elucidate the relative
contribution of the constitutive and inducible form of NOS to
the observed IGF-I-stimulated NO production, we monitored
NO release from the cells which were preincubated for 24 hours
with 1 p.M dexamethasone which is a selective inhibitor of the
inducible NOS [23]. As shown in Figures 2 and 4, preincubation
of HUVEC or RIAEC with dexamethasone did not reduce the
IGF-I-induced NO release, indicating that the increased pro-
duction of NO in response to IGF-I is due to the activation of
the constitutive NOS in endothelial cells.
Signaling cascade leading to the stimulation of endothelial
NOS
It has previously been demonstrated that the activity of
endothelial constitutive NOS is [Ca2 and calmodulin-depen-
dent [13, 14]. We have previously confirmed this finding by the
direct demonstration of NO release from the endothelial cells
exposed to various Ca-mobilizing agonists [16]. To investigate
the signaling cascade involved in the stimulatory effect of IGF-I
on the NOS, we used spectrofluorimetric technique to monitor
[Ca2]1 in individual cells exposed to IGF-I. As shown in Figure
5, IGF-I did not alter [Ca2] in either type of cells.
Next, the effect of a specific tyrosine kinase inhibitor, GEN
on IGF-I-induced NO release was examined. Brief (15 mm)
pretreatment of HUVEC or RIAEC with 20 p.g/ml GEN re-
sulted in a 81% and 79% reduction in peak [NO] responses to
IGF-I, respectively (Figs. 2 and 4). These results suggest that
the IGF-I-stimulated NO synthesis in the endothelial cells is
A HUVEC
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B RIAEC
IGF-1 (1 ng/mI)
Anti-IGF-1 +
JGF-1 (4 nglml)
L-NAME (1 mM)+
IGF-1 (4ng/mI)
(1
+ IGF-1 (4 ng/mI)
mediated via a tyrosine kinase-dependent, rather than
Ca2/calmodulin pathway.
Discussion
In the present study, we have demonstrated using an amper-
ometric NO-sensor that IGF-I causes an immediate dose-
dependent NO production by two types of cultured endothelial
cells, HUVEC and RIAEC. The NO release was characterized
via a by an initial rise and a subsequent sustained elevation and the
peak [NO] responses were significantly suppressed by preincu-
bation of the cells with anti-IGF-I antibody or L-NAME,
confirming the specificity of this effect. Furthermore, the IGF-
I-stimulated immediate NO production was not affected by the
24-hour preincubation with dexamethasone, a known selective
inhibitor of the inducible form of NOS. These findings establish,
for the first time, that IGF-I activates the constitutive form of
IGF-1 (20 ng/mI)
IGF-1 (4 ng/mI)
GEN (20 pg/mI)+
IGF-1 (4 ng/mI)
100 flM NO
A HUVEC
H
2 mm
Fig. 2. Representative recordings of [NO] in
the incubation medium conditioned by
HUVEC or RIAEC prior to and following the
application of IGF-I. IGF-I at the indicated
concentrations was added to the incubation
medium (arrows). Scale bar in the right lower
corner corresponds to the [NO] = 100 nM.
(N=4)
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Fig. 4. Effect of anti-IGF-I antibody, L-NAME, dexamethasone or
GEN on the peak [NO] release by endothelial cells stimulated with 4
ng/ml IGF-I. * and ** indicate P < 0.005 and P < 0.001 vs. IGF-I alone,
respectively.
NOS and stimulates NO production by cultured endothelial
cells.
The culture of renal vascular endothelial cells has presented
significant difficulties and the only success has been reported on
immortalization of glomerular endothelial cells [24, 25]. The
SV4O-transfected RIAEC represent a new stable cell line ex-
pressing the characteristics of differentiated endothelial cells.
Immortalized RIAEC displayed responses to the application of
IGF-l which were essentially similar to those detected in
HUVEC, further supporting the identification of SV4O-trans-
fected cells with the vascular endothelium.
It has been generally accepted that the endothelial constitu-
tive NOS is bound to calmodulin and that the NOS is stimulated
upon elevation of [Ca2]1 resulting in the activation of calmod-
ulin [13—151. We have recently observed using an amperometric
NO-sensor that agents which increase [Ca2]1, that is, alpha-
thrombin, bradykinin and ionomycin induce NO production by
HUVEC, and that the effect of ionomycin is calmidazolium-
inhibitable [16], thus confirming the stimulatory effect of Ca2/
calmodulin system on the endothelial NOS activity [13—15].The
J"ionomycin
(4 IJM)
F
100 sec
Fig. 5. Fluorescence of fura-2-loaded endothelial cells exposed to
JGF-I or ionomycin. IGF-I (4 ng/ml) or ionomycin (4 sM) was added to
the incubation medium (arrows). All values are expressed as mean
SE; N = 4 for HUVEC and N = 5 for RIAEC. No changes in [Ca211 are
seen in response to the addition of IGF-I. Similar results were obtained
with 20 ng/ml IGF-I (data not shown).
above mechanism, however, does not seem to be operant in
endothelial cells stimulated by IGF-I. IGF-I did not alter
[Ca2]1 in either type of endothelial cells, suggesting that an
alternative mediator(s) is involved in the IGF-I-induced in-
crease in NO release.
Endothelial cells express surface receptors for IGF-I [8—10].
The IGF-I receptor is a glycoprotein with two disulfide-linked
alpha-subunits (135 kD) engaged in the ligand binding and two
membrane-spanning beta-subunits (95 kD) containing an intrin-
sic tyrosine kinase activity [1, 2]. Binding of IGF-I to the
receptor alpha-subunit stimulates the intrinsic tyrosine kinase
activity, leading to a multisite autophosphorylation of the
beta-subunit. Receptor tyrosine kinase activation appears to be
essential for most of the effects stimulated by IGF-I. Therefore,
we examined the effect of blockade of the tyrosine kinase
pathway on the IGF-I-induced NO release by cultured endo-
thelial cells. Pretreatment with GEN, a specific inhibitor of
tyrosine kinase, resulted in a blockade of the IGF-I-induced NO
production by HUVEC and RIAEC. Collectively, these data
suggest that IGF-I-induced NO synthesis in the endothelial cells
A HUVEC
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derived relaxing factor, seems to be concomitantly stimulated
by IGF-I [5, 6].
Although highly suggestive of NO involvement in the Va-
sodilatory effect of IGF-I, neither of these studies produced
direct evidence of NO generation by the endothelial cells
stimulated with IGF-I. Since all conclusions were based on the
use of pharmacological inhibitors of NOS which per se produce
vasoconstriction and, consequently, counterbalance the effect
of vasodilatory substances, regardless of their mode of action,
it was important to document the effect of IGF-I on NO
production by endothelial cells. The data presented herein have
fulfilled this requirement.
In conclusion, our findings directly demonstrating the IGF-I-
induced NO release from cultured RIAEC are consistent with
the hypothesis that IGF-I plays an important role in renal
vascular physiology and pathophysiology through NO synthe-
sis. IGF-I produced locally (paracrine effect) and/or systemi-
cally (endocrine effect) may stimulate NOS activity and release
of NO by renal vascular endothelium, thus resulting in renal
vasodilation.
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